ptprf Antibody

What is PTPRF and what cellular functions does it regulate?

PTPRF (Protein Tyrosine Phosphatase Receptor F), also known as Leukocyte Common Antigen Related (LAR) protein, is a transmembrane receptor-type protein tyrosine phosphatase that belongs to the PTP family. It contains an extracellular region, a single transmembrane domain, and two tandem intracytoplasmic catalytic domains . PTPRF functions as a possible cell adhesion receptor with intrinsic protein tyrosine phosphatase activity (PTPase) . It regulates various cellular processes including insulin signaling, cell proliferation, and cell migration . Importantly, PTPRF plays a critical role in the regulation of epithelial cell-cell contacts at adherens junctions and in the control of beta-catenin signaling . The first PTPase domain exhibits enzymatic activity, while the second domain appears to influence the substrate specificity of the first domain .

What is the molecular architecture of PTPRF protein as detected by antibodies?

The full-length PTPRF protein has a molecular weight of approximately 210 kDa, but researchers often detect a smaller 85 kDa band in Western blot applications . This size discrepancy occurs due to proteolytic processing, resulting in a P-subunit that contains the transmembrane and intracellular domains . When selecting antibodies for experimental applications, researchers should consider which region of PTPRF they aim to target. Many commercial antibodies, such as those targeting amino acids 1315-1607 (the cytoplasmic C-terminus of human PTPRF), specifically recognize the processed intracellular domain rather than the complete extracellular portion .

What are the optimal applications for PTPRF antibodies in research?

PTPRF antibodies have been successfully employed in multiple research applications, particularly Western blot (WB) and immunocytochemistry/immunofluorescence (ICC/IF) . According to published literature, these antibodies have been used at dilutions of approximately 1:1000 for Western blot applications . When using PTPRF antibodies for immunocytochemistry, researchers have successfully visualized PTPRF localization in both human and mouse cell models . For optimal results, researchers should follow standardized protocols that include appropriate blocking steps to prevent non-specific binding, and validate antibody performance in their specific experimental system before conducting critical experiments.

How can researchers effectively use PTPRF antibodies to study its role in cancer progression?

For mechanistic studies, PTPRF antibodies can be used to monitor protein expression after experimental manipulation (knockdown or overexpression) to investigate downstream signaling effects, particularly on the ERK1/2 pathway . When PTPRF is overexpressed in cancer cell lines, researchers can use antibodies to confirm successful manipulation and subsequently assess effects on phosphorylation status of downstream targets like ERK, Mnk1, and Myc through Western blot analysis .

What methodological approaches can be used to manipulate PTPRF function with antibodies?

Recent advances have demonstrated that antibodies targeting PTPRF ectodomains can be used to manipulate their dimerization status and thereby regulate intracellular signaling . This approach represents a novel methodology for studying PTPRF function. Researchers have generated monoclonal antibodies specifically designed to induce PTPRF dimerization ectopically, which can suppress PTPRF-dependent cell invasion .

The methodology involves producing and characterizing monoclonal antibodies that target the ectodomain of PTPRF, then validating their effects in cell models where PTPRF activity can be assessed by measuring SRC phosphorylation . For example, antibody RD-43 has been shown to inhibit PTPRF activity and promote its degradation by inducing PTPRF dimerization and facilitating the degradation of these dimers through a secretase-independent pathway . This approach provides researchers with a powerful tool to modulate PTPRF activity in experimental settings without genetic manipulation.

What are the optimal storage and handling conditions for PTPRF antibodies?

For maximum antibody stability and activity, PTPRF antibodies should be aliquoted and stored at ≤ -20°C for long-term storage . For short-term storage (up to several weeks), antibodies can be kept at 2-8°C . To ensure maximum recovery of the product, it is recommended to centrifuge the vial prior to removing the cap . Most commercial PTPRF antibodies are supplied in a liquid formulation, often in a buffer containing components like 10 mM Tris, 50 mM Sodium Chloride, and 0.065% Sodium Azide at pH 7.1 . Researchers should avoid repeated freeze-thaw cycles which can lead to antibody degradation and reduced performance in experimental applications.

How can researchers troubleshoot non-specific binding with PTPRF antibodies?

Non-specific binding is a common challenge when using antibodies for protein detection. For PTPRF antibodies, researchers should consider the following troubleshooting approaches:

• Optimization of blocking conditions: Use a suitable blocking agent (5% non-fat milk or BSA) to reduce background signal.

• Antibody dilution testing: Test a range of antibody dilutions to determine the optimal concentration that provides specific signal while minimizing background.

• Increased washing steps: Implement additional washing steps with appropriate buffers (TBST or PBST) to remove unbound antibodies.

• Validation with positive and negative controls: Include samples with known PTPRF expression levels and samples where PTPRF has been knocked down to confirm specificity.

• Cross-reactivity assessment: Verify that the antibody does not cross-react with related proteins like PTPRD or PTPRS, which share structural similarities with PTPRF .

What experimental controls should be included when studying PTPRF expression in disease models?

When investigating PTPRF expression in disease models, particularly cancer, researchers should incorporate several critical controls:

• Paired normal tissue samples: Include adjacent normal tissue samples from the same patient to establish baseline PTPRF expression.

• Positive control tissues: Include samples known to express PTPRF at detectable levels, such as brain tissue.

• Knockdown/overexpression validation: In cell-based studies, include PTPRF knockdown and overexpression controls to validate antibody specificity and establish the dynamic range of detection.

• Isotype controls: Include appropriate isotype controls when using monoclonal antibodies to distinguish specific from non-specific binding.

• Detection method controls: Include secondary antibody-only controls to assess background signal from detection systems.

How can PTPRF antibodies help elucidate ERK1/2 signaling pathway regulation in cancer?

PTPRF has been identified as a negative regulator of ERK1/2 phosphorylation and its downstream signaling in gastric adenocarcinoma cells . Researchers can use PTPRF antibodies in conjunction with phospho-specific antibodies against ERK1/2 and its downstream targets to investigate this regulatory pathway. Following experimental manipulation of PTPRF levels (either knockdown or overexpression), Western blot analysis with phospho-specific antibodies can reveal changes in the activation status of ERK1/2, Mnk1, and Myc .

This approach has demonstrated that ERK phosphorylation is negatively regulated by PTPRF levels, with phosphorylation of downstream substrates significantly inhibited by PTPRF . The combination of PTPRF antibodies with ERK pathway inhibitors (such as U0126) provides a powerful experimental strategy to dissect the specific contribution of PTPRF to ERK-mediated cellular phenotypes like migration and invasion .

What are the emerging applications of PTPRF ectodomain antibodies in cancer research?

Recent research has explored the use of antibodies targeting PTPRF ectodomains as tools to manipulate receptor dimerization and potentially as therapeutic agents . By inducing PTPRF dimerization ectopically, these antibodies can regulate intracellular signaling events and suppress PTPRF-dependent cell invasion, particularly in breast cancer models .

Researchers interested in this approach should consider:

• Antibody epitope mapping: Characterize the binding sites of antibodies on the PTPRF ectodomain to understand potential functional consequences.

• Dimerization assessment: Employ techniques such as non-reducing SDS-PAGE or cross-linking assays to confirm antibody-induced dimerization.

• Downstream signaling analysis: Monitor changes in PTPRF substrates (such as SRC) phosphorylation status following antibody treatment.

• Degradation pathway investigation: Analyze whether antibody-induced PTPRF dimerization leads to protein degradation and through which cellular pathways.

This emerging application represents a novel approach to modulating PTPRF function in experimental settings and could potentially inform future therapeutic strategies.

How does PTPRF expression correlate with clinical outcomes in cancer patients?

Multivariate Cox regression analysis has established PTPRF as an independent prognostic factor in gastric adenocarcinoma (HR 0.492, 95% CI 0.252–0.959; P=0.037), indicating that PTPRF exerts antitumor effects in this cancer type . These findings suggest that PTPRF antibodies could be valuable tools for prognostic evaluation in clinical cancer samples, particularly in gastric adenocarcinoma where PTPRF downregulation appears to contribute to disease progression.

What methodological approaches can quantify PTPRF expression in clinical samples?

Researchers can employ several complementary methods to quantify PTPRF expression in clinical samples:

• Immunohistochemistry (IHC): Using validated PTPRF antibodies with appropriate scoring systems to categorize expression levels (e.g., low vs. high expression) based on staining intensity and percentage of positive cells.

• Western blot analysis: For frozen tissue samples, Western blotting with PTPRF antibodies provides semi-quantitative assessment of protein expression.

• Quantitative PCR: Measuring PTPRF mRNA levels as a complement to protein expression data.

When implementing these approaches, researchers should establish standardized protocols and scoring criteria to ensure consistent and reproducible results across different samples and studies. This standardization is particularly important for translational research aiming to establish PTPRF as a clinically relevant biomarker.